Q-omics provides the consensus-scored RPS15AP29 profile across patient tissues and cancer cell-line models. RPS15AP29 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPS15AP29 is differentially expressed in 3, with the highest sampling consensus in THCA. Additionally, RPS15AP29 RNA expression shows 9,774 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUAD, THCA, and LAML as cancer lineages where RPS15AP29 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS15AP29 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS15AP29 survival associations across molecular data types. RPS15AP29 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS15AP29 RNA expression–survival associations across cancer types. High RPS15AP29 expression shows unfavorable associations in OV, GBM and UCS, but favorable associations in LUAD, CESC and SKCM. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPS15AP29 RNA expression.
This table summarizes RPS15AP29 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RPS15AP29. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS15AP29 shows lower tumor expression in THCA and KIRP and higher tumor expression in COAD. The THCA box plot shows higher RPS15AP29 RNA expression in normal versus tumor tissue (log2 FC = −0.103, t-test p = .005).
This table shows molecular features associated with RPS15AP29 in patient tissues and cancer cell lines. In patient samples, RPS15AP29 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
